Cas:1086138-36-4 Bis[2-(di-1-adamantylphosphino)ethyl]amine manufacturer & supplier

Chemical Name:Bis[2-(di-1-adamantylphosphino)ethyl]amine

CAS.NO:1086138-36-4

Synonyms:BIS[2-(DIADAMANTYLPHOSPHINO)ETHYL]AMINE;Bis[2-(di-1-adamantylphosphino)ethyl]amine;bis(2-(Di(adamantan-1-yl)phosphino)ethyl)amine

Molecular Formula:C₄₄H₆₉NP₂

Molecular Weight:673.97300

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:39.21000

Exact Mass:673.49100

LogP:11.80590

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 3335

Packing Group:

Contact us for information like BIS[2-(DIADAMANTYLPHOSPHINO)ETHYL]AMINE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,bis(2-(Di(adamantan-1-yl)phosphino)ethyl)amine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,BIS[2-(DIADAMANTYLPHOSPHINO)ETHYL]AMINE Use and application,Bis[2-(di-1-adamantylphosphino)ethyl]amine technical grade,usp/ep/jp grade.

Related News: Process: The importance of safety is obvious. The research and development of specialty drug substances (especially high-barrier generic drug substance drugs) usually need to avoid the original process patents, and some chemicals are developed because of the complex structure or the harsh synthetic conditions The synthetic route is more difficult, so the importance of process design capabilities of API companies is becoming more important. Bis[2-(di-1-adamantylphosphino)ethyl]amine manufacturer The FDA also said that the labeling of the diagnostic, which comes in different versions, included performance claims that did not match up with results seen in clinical studies—and that the data Innova submitted for review “was identical to data previously provided by other manufacturers” in separate requests for emergency COVID authorizations, raising additional questions. Bis[2-(di-1-adamantylphosphino)ethyl]amine supplier Process: The importance of safety is obvious. The research and development of specialty drug substances (especially high-barrier generic drug substance drugs) usually need to avoid the original process patents, and some chemicals are developed because of the complex structure or the harsh synthetic conditions The synthetic route is more difficult, so the importance of process design capabilities of API companies is becoming more important. Bis[2-(di-1-adamantylphosphino)ethyl]amine vendor The FDA also said that the labeling of the diagnostic, which comes in different versions, included performance claims that did not match up with results seen in clinical studies—and that the data Innova submitted for review “was identical to data previously provided by other manufacturers” in separate requests for emergency COVID authorizations, raising additional questions. Bis[2-(di-1-adamantylphosphino)ethyl]amine factory To persuade doctors to stop treatment for a traditionally continuous therapy, AbbVie and J&J likely also need to show that doing so won’t hurt patients’ chance at successful retreatment if their cancer does rebound early.